Repevax, Adacel-Polio, Triaxis-Polio (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine (Tdap-IPV))End of procedure: 21/05/2025Date of publication: 01/08/2025
Instructions for RMS when preparing the PAR based on the FAR (July 2025)PAR template (empty) - when prepared based on FAR (July 2025)
CMDh letter for MAHs for medicinal products containing active ingredients in the form of Mesilates, Isetionates, Tosilates or Besilates (February 2008)
Bridging requirements for formulations in a well-establish use application
In follow up to the publication of the ICH E20 draft Guideline “Adaptive Designs for Clinical Trials” in June 2025, the EWG has also prepared a Step 2 informational presentation.
The ICH Secretariat is pleased to announce the release of Training Modules 1 to 7 on ICH Q2(R2) “Validation of Analytical Procedures” and ICH Q14 “Analytical Procedure Development”.
In follow up to the publication of the ICH M4Q(R2) draft revised Guideline in May 2025, the EWG has also prepared a Step 2 informational presentation.
The ICH E20 draft Guideline on “Adaptive Design for Clinical Trials” has reached Step 2b of the ICH Process on 25 June 2025 and entered the Step 3 public consultation period.
The ICH E21 draft Guideline on “Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials” reached Step 2b of the ICH Process in May 2025 and has entered the consultation period.
IMPLEMENTATION OF THE VARIATIONS FRAMEWORK Marketing authorisation holders (MAHs) and national competent authorities should follow certain principles to facilitate a smooth transition to the new variations framework. Type-IB and II variations (including grouped Type-IA variations) For Type-IB and / or Type-II variations submitted before 15 January 2026: These types of variations will follow the current [...]